Business Wire

Sky Labs CART-I Invited to a Clinical Study of Oxford University Professor Betts

22.2.2021 17:00:00 EET | Business Wire | Press release

Share

Sky Labs, a healthcare start-up, announced that CART-I, its ring-type heart-monitoring device, had been provided for Timothy Betts, professor of medicine at Oxford University, for his clinical research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005010/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The world’s first ring-type heart-monitoring device, CART-I developed by Sky Labs. The CART (Cardio Tracker) – I, a ring-type medical device monitors heart signals and detects diseases by using optical sensors. The photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger and continuously measures the irregular pulse waves of atrial fibrillation. Electrocardiogram (ECG) can be also measured by simply placing the fingers on the metal part of the ring. Sky Labs provided its CART-I for clinical research of professor Timothy Betts at Oxford University. Professor Betts plans to conduct a clinical study with Sky Labs CART-I to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed. (Photo: Business Wire)

Professor Timothy Betts is a cardiologist and arrhythmia specialist. He is a key figure for clinical research in cardiac rhythm management and associate professor of cardiovascular medicine at Oxford University. He is also a member of the Oxford Biomedical Research Center and the UK representative on the EHRA National Cardiac Societies Committee.

Atrial fibrillation patients are advised to take anticoagulants to prevent the risk of stroke. However, it is not easy to identify the symptoms. Professor Betts plans to conduct a clinical study with Sky Labs CART-I, Medtronic Reveal LINQ II and Apple Watch to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed.

Fifty patients recruited for the study will be inserted with a Reveal LINQ II implantable cardiac monitor (ICM). Then they will receive a Sky Labs CART-I ring or an Apple Watch. The ability of the ring and the watch to monitor heart rhythm and alert atrial fibrillation episodes will be analyzed in comparison with the ICM.

CART-I is the world’s first ring-type heart-monitoring device. The photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger and continuously measures the irregular pulse waves of atrial fibrillation. Electrocardiogram (ECG) can be also measured by simply placing the fingers on the metal part of the ring.

Professor Timothy Betts said, “I’m pleased to conduct a study to monitor the atrial fibrillation of patients by using CART-I and utilize the data to guide atrial fibrillation treatment. CART-I featuring innovative design and multiple functions will be of great help to patients and medical staffs.”

Jack Lee, CEO of Sky Labs, said, “The study will be an opportunity for us to enter the global healthcare market. CART-I will make a good combination with the ICM in monitoring heart rhythm and providing meaningful data for patients and doctors.”

Sky Labs’ CART-I won the Digital Health & Technology Competition of the European Society of Cardiology for 2 consecutive years from 2018. The company was selected as the ‘technology pioneer’ of the World Economic Forum 2019 and invited to the annual forum.

About Sky Labs

Sky Labs developed CART (Cardio Tracker) – I, a ring-type medical device to monitor heart signals and detect diseases by using optical sensors. It monitors atrial fibrillation, which cannot be detected in advance, 24/7. The results can be checked in real time on the CART-app of your smartphone. Very light and water-resistant, the CART ring is easy to use and causes no inconvenience to your daily life. Winning the final of the Grants4Apps held by Bayer, a German multinational pharmaceutical company, in 2017, Sky Labs attracted investment from Bayer Headquarters. Sky Labs and the Charité in Germany, one of Europe’s largest hospitals, have been considering collaborative clinical research in heart-related diseases since May 2018. It is the only Korean company which won the Digital Health and Technology Competition of the European Society of Cardiology for 2 consecutive years. In addition, the company was invited as a technology pioneer to the World Economic Forum 2019.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Sky Labs
Meet the sun
Shinhwa Park
+82.2.739.4931
sh.park@meetthesun.co.kr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye